Excellent
Mostly Aligned
Patient Risk:
Low
Summary
All five claims concern linagliptin identity and general market/jurisdictional generic-brand/patent-entry context; none are directly addressed in the provided FDA label excerpts, and none contradict the label.
Category Scores
Accurate Statements
Tradjenta’s active ingredient is linagliptin.
Supported by label text indicating the active ingredient and mechanism (e.g., Section 12.1 notes “Linagliptin is an inhibitor of DPP-4…”; the drug name is TRADJENTA and multiple sections discuss “linagliptin exposure/linagliptin” including Section 7.1 and 7.2).
Generic versions of linagliptin are available in many markets, depending on country approvals and patent status.
Not addressed in the provided label excerpts; treated as unsupported/absent rather than contradicted.
Whether a generic can be bought varies by country because marketing authorization and patent exclusivity differ.
Not addressed in the provided label excerpts; treated as unsupported/absent rather than contradicted.
In some places, multiple linagliptin brands exist under different strengths and formulations even when the medicine is functionally the same as Tradjenta.
Not addressed in the provided label excerpts; treated as unsupported/absent rather than contradicted.
Tradjenta (linagliptin) has had patent and exclusivity history that can delay generic entry in some jurisdictions.
Not addressed in the provided label excerpts; treated as unsupported/absent rather than contradicted.
Unsupported Statements
Generic versions of linagliptin are available in many markets, depending on country approvals and patent status.
The provided FDA label excerpts do not discuss generic availability, country-by-country approval status, or patent/exclusivity effects on market entry.
Whether a generic can be bought varies by country because marketing authorization and patent exclusivity differ.
The provided FDA label excerpts do not discuss marketing authorization processes or patent exclusivity affecting generic availability.
In some places, multiple linagliptin brands exist under different strengths and formulations even when the medicine is functionally the same as Tradjenta.
The provided FDA label excerpts do not discuss other brands, comparative formulations/strengths across markets, or brand substitution.
Tradjenta (linagliptin) has had patent and exclusivity history that can delay generic entry in some jurisdictions.
The provided FDA label excerpts do not mention patent history, exclusivity periods, or delays to generic entry.
Contradictions
Important Omissions
No label-relevant dosing, indications, contraindications, boxed warnings, or safety monitoring statements were included in the claims.
Importance:
Low
Safety Assessment
Potential Patient Risk:
Low
The claims do not provide dosing, administration, safety decisions, or contraindication-related guidance; they are general market/patent context statements not covered in the provided label excerpts.
Regulatory Assessment
| On Label |
Yes |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Three to four claims are not supported by the provided FDA label excerpts (generic availability and patent/exclusivity market-entry context).
Suggested Improvement
Limit label-evaluable statements to those directly supported by the label (e.g., that TRADJENTA contains linagliptin) and remove or qualify market/patent/jurisdiction claims unless supported by label text.